Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

5 terminated/withdrawn out of 10 trials

Success Rate

16.7%

-69.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
8(80.0%)
Phase 1
2(20.0%)
10Total
Phase 2(8)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT05077800Phase 2Active Not Recruiting

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Role: collaborator

NCT06896188Phase 1Recruiting

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

Role: collaborator

NCT05239182Phase 2Terminated

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Role: collaborator

NCT04239092Phase 1Terminated

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Role: lead

NCT05010629Phase 2Active Not Recruiting

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Role: collaborator

NCT03678883Phase 2Active Not Recruiting

9-ING-41 in Patients with Advanced Cancers

Role: lead

NCT04218071Phase 2Completed

Actuate 1901: 9-ING-41 in Myelofibrosis

Role: lead

NCT04832438Phase 2Withdrawn

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Role: lead

NCT05116800Phase 2Withdrawn

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Role: collaborator

NCT04906876Phase 2Withdrawn

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Role: collaborator

All 10 trials loaded